Christophe Van Dijck

Dr. Christophe Van Dijck

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
IBIrith De Baetselier
Irith De Baetselier
CDChristophe Van Dijck
Christophe Van Dijck
CKChris Kenyon
Chris Kenyon
JCJasmine Coppens
Jasmine Coppens
JMJohan Michiels
Johan Michiels
BVBea Vuylsteke
Bea Vuylsteke
The magnitude of the 2022 multi-country monkeypox virus (MPXV) outbreak has surpassed any preceding outbreak. It is unclear whether asymptomatic or otherwise undiagnosed infections are fuelling this epidemic. In this study, we aimed to assess whether undiagnosed infections occurred among men attending a Belgian sexual health clinic in May 2022. We retrospectively screened 224 samples collected for gonorrhea and chlamydia testing using an MPXV PCR assay and identified MPXV-DNA-positive samples from four men. At the time of sampling, one man had a painful rash, and three men had reported no symptoms. Upon clinical examination 21–37 days later, these three men were free of clinical signs, and they reported not having experienced any symptoms. Serology confirmed MPXV exposure in all three men, and MPXV was cultured from two cases. These findings show that certain cases of monkeypox remain undiagnosed and suggest that testing and quarantining of individuals reporting symptoms may not suffice to contain the outbreak.

1 October 2012 in Laboratory Investigation
Verified
Journal Article
Closed access
SFSven M Francque
Sven M Francque
WLWim Laleman
Wim Laleman
LVLen Verbeke
Len Verbeke
CSChristophe Van Steenkiste
Christophe Van Steenkiste
CCChristophe Casteleyn
Christophe Casteleyn
PMPeter Michielsen
Peter Michielsen

28 February 2018 in Bulletin of the World Health Organization
Verified
Journal Article
Open access
CDChristophe Van Dijck
Christophe Van Dijck
EVErika Vlieghe
Erika Vlieghe
JCJanneke Arnoldine Cox
Janneke Arnoldine Cox
To review the effectiveness of antibiotic stewardship interventions in hospitals in low- and middle-income countries. We searched MEDLINE®, Embase®, Cochrane Central Register of Controlled Trials and regional indexes for studies of interventions to improve appropriate prescribing and use of antibiotics for hospitalized patients in low- and middle-income countries. We included controlled trials, controlled before-and-after studies and interrupted time-series studies published up to December 2017. We report prescribing, clinical and microbiological outcomes using a narrative approach. We screened 7342 original titles and abstracts, assessed 241 full-text articles and included 27 studies from 2 low-income and 11 middle-income countries. We found a medium (11 studies) or high risk (13 studies) of bias. Generally, all types of interventions (structural, persuasive and enabling) and intervention bundles were reported to improve prescribing and clinical outcomes. However, the studied interventions and reported outcomes varied widely. The most frequent intervention was procalcitonin-guided antibiotic treatment (8 of 27 studies, all randomized controlled trials). The intervention was associated with a relative risk for patients receiving antibiotics ranging between 0.40 and 0.87. The majority of studies reported a positive effect of hospital antibiotic stewardship interventions. However, we cannot draw general conclusions about the effectiveness of such interventions in low- and middle-income countries because of low study quality, heterogeneity of interventions and outcomes, and under-representation of certain settings. To strengthen the evidence base, action needs to be taken to address these shortcomings.

2 September 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CDChristophe Van Dijck
Christophe Van Dijck
NHNiel Hens
Niel Hens
CKChris Kenyon
Chris Kenyon
ATAchilleas Tsoumanis
Achilleas Tsoumanis
We used a network model to simulate a mpox epidemic among men who have sex with men. Our findings suggest that unrecognized infections have an important impact on the epidemic, and that vaccination of individuals at highest risk of infection reduces epidemic size more than post-exposure vaccination of sexual partners.

5 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
IBIrith De Baetselier
Irith De Baetselier
CDChristophe Van Dijck
Christophe Van Dijck
CKChris Kenyon
Chris Kenyon
JCJasmine Coppens
Jasmine Coppens
DBDorien Van Den Bossche
Dorien Van Den Bossche
TGthe Monkeypox study group
the Monkeypox study group
Background Monkeypox is transmitted by close contact with symptomatic cases, and those infected are assumed to be uniformly symptomatic. Evidence of subclinical monkeypox infection is limited to a few immunological studies which found evidence of immunity against orthopoxviruses in asymptomatic individuals who were exposed to monkeypox cases. We aimed to assess whether asymptomatic infections occurred among individuals who underwent sexually transmitted infection (STI) screening in a large Belgian STI clinic around the start of the 2022 monkeypox epidemic in Belgium. Methods Anorectal and oropharyngeal swabs collected for gonorrhoea/chlamydia screening from May 1 until May 31, 2022 were retrospectively tested by a monkeypox-specific PCR. Cases with a positive PCR result were recalled to the clinic for case investigation, repeat testing and contact tracing. Findings In stored samples from 224 men, we identified three cases with a positive anorectal monkeypox PCR. All three men denied having had any symptoms in the weeks before and after the sample was taken. None of them reported exposure to a diagnosed monkeypox case, nor did any of their contacts develop clinical monkeypox. Follow-up samples were taken 21 to 37 days after the initial sample, by which time the monkeypox-specific PCR was negative, likely as a consequence of spontaneous clearance of the infection. Interpretation The existence of asymptomatic monkeypox infection indicates that the virus might be transmitted to close contacts in the absence of symptoms. Our findings suggest that identification and isolation of symptomatic individuals may not suffice to contain the outbreak. Funding Institutional funding Evidence before this study Similar to smallpox, monkeypox is transmitted through close contact with symptomatic cases, and 100% of those infected are assumed to develop symptoms. These features imply that an outbreak in the general population tends towards extinction with relatively minor hygienic measures, as observed in several outbreaks in endemic regions. If, however, asymptomatic transmission occurs, the outbreak becomes much more difficult to contain. We searched PubMed and Google Scholar for evidence of asymptomatic human monkeypox, using the search terms “monkeypox” AND (“asymptomatic” OR “subclinical”), and included peer-reviewed reports published until June 17, 2022. We identified seven original reports in three different epidemiological settings which reported indirect, immunological evidence of asymptomatic monkeypox infection in a small number of people who were exposed to the virus. We did not find any study that provided direct evidence of the virus in asymptomatic individuals. Added value of this study By retrospectively screening clinical samples collected for sexually transmitted infection screening in our centre throughout May 2022 with a monkeypox-specific PCR, we found evidence of asymptomatic monkeypox virus infection in three individuals. Implications of all the available evidence The existence of asymptomatic monkeypox infection indicates that the virus may be transmitted in the absence of symptoms. This risk can be further quantified by studying viral dynamics in contacts of symptomatic and asymptomatic monkeypox cases. Our findings suggest that identification and isolation of symptomatic individuals may not suffice to contain the outbreak.

23 March 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
TBTessa de Block
Tessa de Block
JLJolein Gyonne Elise Laumen
Jolein Gyonne Elise Laumen
CDChristophe Van Dijck
Christophe Van Dijck
SASaïd Abdellati
Saïd Abdellati
IBIrith De Baetselier
Irith De Baetselier
CKChris Kenyon
Chris Kenyon
In this study, we characterized all oropharyngeal and anorectal isolates of Neisseria spp. in a cohort of men who have sex with men. This resulted in a panel of pathogenic Neisseria (N. gonorrhoeae [n = 5] and N. meningitidis [n = 5]) and nonpathogenic Neisseria (N. subflava [n = 11], N. mucosa [n = 3] and N. oralis [n = 2]). A high proportion of strains in this panel were resistant to azithromycin (18/26) and ceftriaxone (3/26). Whole genome sequencing (WGS) of these strains identified numerous mutations that are known to confer reduced susceptibility to azithromycin and ceftriaxone in N. gonorrhoeae. The presence or absence of these known mutations did not explain the high level resistance to azithromycin (>256 mg/L) in the nonpathogenic isolates (8/16). After screening for antimicrobial resistance (AMR) genes, we found a ribosomal protection protein, Msr(D), in these highly azithromycin resistant nonpathogenic strains. The complete integration site originated from Streptococcus pneumoniae and is associated with high level resistance to azithromycin in many other bacterial species. This novel AMR resistance mechanism to azithromycin in nonpathogenic Neisseria could be a public health concern if it were to be transmitted to pathogenic Neisseria. This study demonstrates the utility of WGS-based surveillance of nonpathogenic Neisseria.